



## Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

October 2, 2019

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming [Chardan Annual Genetic Medicines Conference](#) at 8:30 a.m. ET on October 8<sup>th</sup> in New York, NY.

A live audio webcast of the Chardan presentation will be available on the Events page of the Investors section of the Company website. A replay of the Chardan presentation will also be archived for approximately 30 days on the Events & Presentations page.

### About Solid Biosciences

Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit [www.solidbio.com](http://www.solidbio.com).

### Investor Contact:

Carlo Tanzi, Ph.D.  
Kendall Investor Relations  
617-337-4680  
[investors@solidbio.com](mailto:investors@solidbio.com)

### Media Contact:

Lindsay Deefholts  
ScientPR  
416-301-7966  
[media@solidbio.com](mailto:media@solidbio.com)



Source: Solid Biosciences Inc.